{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:44:32Z","timestamp":1789152272233,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.neurot.2026.e00922","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:41:23Z","timestamp":1780515683000},"page":"e00922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study"],"prefix":"10.1016","volume":"23","author":[{"given":"Aurora","family":"Zangh\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Sofia","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Robusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Claudia","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neurot.2026.e00922_bib1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41593-022-01097-3","article-title":"Identification of early neurodegenerative pathways in progressive multiple sclerosis","volume":"25","author":"Kaufmann","year":"2022","journal-title":"Nat Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00922_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives","volume":"18","author":"D\u2019Amico","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00922_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00922_bib4","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207768","article-title":"Association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity in people with MS","volume":"102","author":"Cagol","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00922_bib5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","article-title":"Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis","volume":"79","author":"Cagol","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00922_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.26281","article-title":"Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis","volume":"91","author":"Bischof","year":"2022","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00922_bib7","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/brain\/awab132","article-title":"Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement","volume":"144","author":"Ontaneda","year":"2021","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00922_bib8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00702-024-02786-y","article-title":"Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms","volume":"131","author":"Jellinger","year":"2024","journal-title":"J Neural Transm"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00922_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00922_bib10","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis","volume":"14","author":"Hauser","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2026.e00922_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.106994","article-title":"Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: a multicenter cohort study","volume":"107","author":"Te\u0161ija","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00922_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105888","article-title":"Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis","volume":"91","author":"Hersh","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00922_bib13","article-title":"GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis","volume":"awaf433","author":"Maceski","year":"2025","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00922_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00922_bib15","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/ene.15910","article-title":"Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotype","volume":"30","author":"Zangh\u00ec","year":"2023","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00922_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12883-014-0171-6","article-title":"The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population","volume":"14","author":"Goretti","year":"2014","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00922_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00922_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","article-title":"FreeSurfer","volume":"62","author":"Fischl","year":"2012","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00922_bib19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.neuroimage.2012.02.084","article-title":"Within-subject template estimation for unbiased longitudinal image analysis","volume":"61","author":"Reuter","year":"2012","journal-title":"Neuroimage"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00922_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.25145","article-title":"Deep gray matter volume loss drives disability worsening in multiple sclerosis","volume":"83","author":"Eshaghi","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00922_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2017.08.009","article-title":"Quantitative analysis of four protein biomarkers: an automated microfluidic cartridge-based method and its comparison to colorimetric ELISA","volume":"451","author":"Dysinger","year":"2017","journal-title":"J Immunol Methods"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00922_bib22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1177\/1352458518808204","article-title":"Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis","volume":"25","author":"Strober","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2026.e00922_bib23","article-title":"The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis","volume":"59","author":"Cagol","year":"2025","journal-title":"Lancet Reg Health \u2013 Europe"},{"issue":"17_supplement_2","key":"10.1016\/j.neurot.2026.e00922_bib24","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1212\/WNL.0000000000202543","article-title":"Effect of longer-term ofatumumab treatment on disability progression and brain volume change (S16.009)","volume":"100","author":"Cohen","year":"2023","journal-title":"Neurology"},{"issue":"737","key":"10.1016\/j.neurot.2026.e00922_bib25","doi-asserted-by":"crossref","first-page":"eadi0295","DOI":"10.1126\/scitranslmed.adi0295","article-title":"B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans","volume":"16","author":"Wang","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2026.e00922_bib26","article-title":"Molecular mechanisms associated with multiple sclerosis progression, severity and phenotype","author":"Kosa","year":"2022","journal-title":"medRxiv"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00922_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.27034","article-title":"Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00922_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/brain\/awh670","article-title":"Reduced brain functional reserve and altered functional connectivity in patients with multiple sclerosis","volume":"129","author":"Cader","year":"2005","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00922_bib29","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00922_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00922_bib31","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1093\/brain\/awaf331","article-title":"Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types","volume":"148","author":"Willard","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e00922_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","article-title":"Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses","volume":"12","author":"Giovannoni","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00922_bib33","doi-asserted-by":"crossref","first-page":"106989","DOI":"10.1016\/j.msard.2026.106989","article-title":"Lost in space, lost in time: a clinician\u2019s proposed approach to the diagnosis of multiple sclerosis","volume":"107","author":"Wafa","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00922_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251369747","article-title":"A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles","volume":"18","author":"Zangh\u00ec","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00922_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.106989","article-title":"Lost in space, lost in time: a clinician\u2019s proposed approach to the diagnosis of multiple sclerosis","volume":"107","author":"Wafa","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00922_bib36","series-title":"Pain: a review guide","first-page":"123","article-title":"Observational studies: uses and limitations","author":"Hess","year":"2019"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00922_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40263-020-00734-4","article-title":"Cognitive efficacy of pharmacologic treatments in multiple sclerosis: a systematic review","volume":"34","author":"Chen","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2026.e00922_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2017.08.019","article-title":"Proposed cut scores for tests of the brief international cognitive assessment of multiple sclerosis (BICAMS)","volume":"381","author":"Beier","year":"2017","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00922_bib39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/13524585211049397","article-title":"Interpreting change on the symbol digit modalities test in people with relapsing multiple sclerosis using the reliable change methodology","volume":"28","author":"Weinstock","year":"2022","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00922_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"12","author":"Benedict","year":"2006","journal-title":"J Int Neuropsychol Soc"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:34:38Z","timestamp":1788986078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1878747926000929"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00922","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00922"}}